-
Product Insights
NewLikelihood of Approval Analysis for Vulvovaginal Candidiasis
Overview How likely is it that the drugs in Vulvovaginal Candidiasis will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vulvovaginal Candidiasis Overview An excessive growth of yeast in the vagina that...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – STI-103 in Muscle Spasticity
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - STI-103 in Muscle Spasticity report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.STI-103 in Muscle Spasticity Drug Details:STI-103 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – STI-6643 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - STI-6643 in Solid Tumor report and make more profitable business decisions. How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – STI-1492 in Relapsed Multiple Myeloma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.STI-1492 in Relapsed Multiple Myeloma Drug Details:Gene-modified cell therapy is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – STI-6129 in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - STI-6129 in Relapsed Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.STI-6129 in Relapsed Multiple Myeloma Drug Details:Monoclonal antibody conjugate is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – STI-1492 in Refractory Multiple Myeloma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.STI-1492 in Refractory Multiple Myeloma Drug Details:Gene-modified cell therapy is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – STI-6129 in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - STI-6129 in Refractory Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.STI-6129 in Refractory Multiple Myeloma Drug Details:Monoclonal antibody conjugate is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – STI-6129 in Primary Systemic Amyloidosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - STI-6129 in Primary Systemic Amyloidosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.STI-6129 in Primary Systemic AmyloidosisDrug Details:Monoclonal antibody conjugate is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Etrasimod in Atopic Dermatitis (Atopic Eczema)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Etrasimod in Atopic Dermatitis (Atopic Eczema) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Etrasimod in Atopic Dermatitis (Atopic Eczema) Drug Details: Etrasimod...
-
Sector Analysis
Turkey Wind Power Market Analysis by Size, Installed Capacity, Power Generation, Regulations, Key Players and Forecast to 2035
Turkey Wind Power Market Report Overview The cumulative installed capacity for wind power in Turkey was 11.97GW in 2022. It is expected to achieve a CAGR of more than 6% during 2022-2035. The Turkey wind power market research report highlights installed capacity and power generation trends from 2010 to 2035. The report discusses the key insights about the major active and upcoming wind power plants in Turkey. Turkey Wind Power Market Outlook, 2022-2035 (MW) Buy the Full Report for More...